INTRODUCTION: The optimal choice of first-line chemotherapy for @entity1 with relapse of @entity189 ( @entity189 ) after perioperative @entity900 -based chemotherapy (PCBC) is unclear. We investigated the outcomes with @entity900 rechallenge versus a non- @entity900 regimen in @entity1 with recurrent metastatic @entity189 after PCBC in a multicenter retrospective study. @entity1 AND METHODS: Individual @entity1 -level data were collected for @entity1 who had received various first-line chemotherapy regimens for advanced @entity189 after previous PCBC. Cox proportional hazards models were used to investigate the prognostic ability of the type of perioperative and first-line chemotherapy to independently affect @entity1349 ( @entity1349 ) and progression-free survival (PFS) after accounting for known prognostic factors. RESULTS: Data were available for 145 @entity1 (12 centers). The mean age was 62 years; the Eastern Cooperative Oncology Group (ECOG) performance status (PS) was > 0 for 42.0% of the @entity1 . Of the 145 @entity1 , 63% had received @entity900 -based first-line chemotherapy. The median time from previous chemotherapy (TFPC) was 6.2 months (range, 1-154 months). The median @entity1349 was 22 months (95% confidence interval [CI], 18-27 months), and the median PFS was 6 months (95% CI, 5-7 months). A better ECOG PS and a longer TFPC (> 12 months vs.   <= 12 months; hazard ratio [HR], 0.32; 95% CI, 0.20-0.52; P  < .001) was prognostic for @entity1349 and PFS. @entity900 -based chemotherapy was associated with poor @entity1349 (HR, 1.86; 95% CI, 1.13-3.06; P  = .015), which appeared to be pronounced in those @entity1 with a TFPC of   <= 12 months. Retreatment with @entity900 in the first-line setting was associated with worse @entity1349 (HR, 3.38; P  < .001). CONCLUSION: The results of the present retrospective analysis suggest that for @entity1 who have undergone previous PCBC for @entity189 , rechallenging with @entity900 might confer a poorer @entity1349 , especially for those with progression within  <  1  year.

@entity900 - Versus Non- XXXX -based First-Line Chemotherapy for Advanced @entity189 Previously Treated With Perioperative @entity900 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin', 'Cisplatin'] @entity189 :: ('MESH:D002277', 'Disease') :: ['urothelial carcinoma', 'UC'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity900 :: (MESH:D002945,Chemical) :: ['Cisplatin']
